Cingulate Temettü

Temettü kriter kontrolleri 0/6

Cingulate şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.3%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$6.27
Gelecekteki Temettü Verimi	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Aug 26

Cingulate Q2 GAAP EPS of -$0.36

Aug 11

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Apr 04

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CING şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CING şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Cingulate Piyasaya Karşı Temettü Getirisi

CING temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CING)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.6%
Sektör Ortalaması (Pharmaceuticals)	2.3%
Analist tahmini (CING) (3 yıla kadar)	n/a

Önemli Temettü: CING şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CING şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CING şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CING herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Cingulate Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

The Nasdaq Hearings Panel Grants Cingulate's Request for an Exception to Demonstrate Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing Through August 23, 2024

Cingulate Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market

Cingulate Inc., Annual General Meeting, Jun 11, 2024

Cingulate Inc. Regains Compliance with the Board Composition Requirements of Nasdaq Set in Nasdaq Listing Rule 5605

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. Announces Promotion of Jennifer Callahan as Chief Financial Officer

Cingulate Inc. has filed a Follow-on Equity Offering in the amount of $26 million.

Cingulate Receives Non-Compliance Notice from Nasdaq

Cingulate Inc. and Cingulate Therapeutics LLC Announce Resignation of Officer

Scott Applebaum Provides Cingulate Inc. with Notice of His Resignation from the Board of Directors

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTX-2103 (Buspirone)

Cingulate Inc. has filed a Follow-on Equity Offering.

The Listing Qualifications Staff of The Nasdaq Stock Market LLC Determines to Delist Cingulate's Securities from Nasdaq Unless it Timely Requests Hearing Before the Nasdaq Hearings Panel

Cingulate Inc. to Host CNS Key Opinion Leader Panel in New York City Expert Analysis of Cingulate, it’s Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations

Cingulate Weighs Reverse Stock Split to Avoid Delisting

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $4 million.

New major risk - Shareholder dilution

New major risk - Negative shareholders equity

Cingulate Inc. Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Cingulate Inc. Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for Adhd

Cingulate Inc. Successfully Manufactures Clinical Supply Initiation of Pediatric Phase 3 Studies to Commence in July and August

New major risk - Market cap size

Cingulate Completes Phase 3 Adult Trial of Ctx-1301 (Dexmethylphenidate) for Adhd

Cingulate Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

Cingulate Inc., Annual General Meeting, Jun 15, 2023

Forecast to breakeven in 2025

No longer forecast to breakeven

Cingulate Inc. Announces Resignation of Jeff Conroy from the Board of Directors

Cingulate Inc. Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Independent Director recently bought US$75k worth of stock

Cingulate Inc. Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

Cingulate Inc. Provides Clinical Update

Cingulate Inc. Announces the Resignation of Jeff Hargroves from the Board of Directors

Cingulate Presents Data for its Triple-Release Buspirone Product Candidate: CTx-2103

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Cingulate Inc. Appoints Scott Applebaum as Class III Director

Cingulate Q2 GAAP EPS of -$0.36

Cingulate Inc. Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

Cingulate Inc. Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Cingulate Inc. Announces First Subject Dosing in its Human Formulation Study of CTX-2103 (Buspirone) for the Treatment of Anxiety

Cingulate Inc., Annual General Meeting, Jun 08, 2022

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$89k worth of stock

Cingulate Inc Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin